DYN
Dyne Therapeutics Inc.
$19.27
-$0.15(-0.77%)
54
Overall
60
Value
58
Tech
44
Quality
Market Cap
$1.87B
Volume
4.44M
52W Range
$6.36 - $29.72
Target Price
$35.38
Company Overview
| Mkt Cap | $1.87B | Price | $19.27 |
| Volume | 4.44M | Change | -0.77% |
| P/E Ratio | -5.9 | Open | $19.51 |
| Revenue | -- | Prev Close | $19.42 |
| Net Income | $-317.4M | 52W Range | $6.36 - $29.72 |
| Div Yield | N/A | Target | $35.38 |
| Overall | 54 | Value | 60 |
| Quality | 44 | Technical | 58 |
No chart data available
About Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Dyne Therapeutics Announces Upsized Public Offering
TipRanks Auto-Generated Newsdesk•3 days ago
Dye & Durham Faces Financial Filing Delays Amid MCTO Extension
TipRanks Canadian Auto-Generated Newsdesk•3 days ago
Dye & Durham Seeks Court Relief for Shareholder Meeting Amid Audit Delays
TipRanks Canadian Auto-Generated Newsdesk•4 days ago
Dyne Therapeutics Reports Positive Phase 1/2 Trial Results
TipRanks Auto-Generated Newsdesk•5 days ago
Dye & Durham Announces Board Restructuring and Strategic Alignment with OneMove
TipRanks Canadian Auto-Generated Newsdesk•8 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DYN | $19.27 | -0.8% | 4.44M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |